Pharma BD Deal Intelligence
Roche paid $11B for the Corange group to create the world's largest diagnostics company, combining molecular diagnostics with Boehringer Mannheim's immunochemistry platforms. The deal established Roche Diagnostics' $15B+ annual revenue base and its integrated diagnostics-plus-pharma strategy.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
UBS analyst Birgit Kulhoff estimated the purchase price was equivalent to an earnings multiple of about 25, noting this is not exactly the cheapest deal for…
Roche Holdings, Ltd. acquires Boehringer Mannheim in merger, forming the largest diagnostic manufacturer in the world with 13,500 employees and yearly sales…
Roche's acquisition of Boehringer Mannheim eclipsed Abbott Laboratories as the world's largest diagnostics company, combining complementary portfolios across…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Roche acquired the Corange group, parent of Boehringer Mannheim and DePuy, for approximately $11 billion (DM 18.7 billion), creating the world's largest diagnostics company with combined yearly sales exceeding $2.5 billion in the diagnostics segment.
Roche Holding AG completed its acquisition of Corange Ltd. (Boehringer Mannheim Group) for $11B.
FTC required Retavase sale; EU required PCR licensing. Regulatory step in Roche Holding AG's acquisition process for Corange Ltd. (Boehringer Mannheim Group).
Boehringer Mannheim rebranded as Roche Diagnostics, 13,500 employees. Part of Roche Holding AG's $11B deal to acquire Corange Ltd. (Boehringer Mannheim Group).
Established Roche as undisputed diagnostics leader, position held today. Assessment of Roche Holding AG's $11B acquisition of Corange Ltd. (Boehringer Mannheim Group) and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) (this deal) | 1997 | $11.0B | 88 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 1997 deals · Roche Holding AG deals · Metabolic deals